Contact us
![]() |
customer@davidpublishing.com |
![]() |
3275638434 |
![]() |
![]() |
| Paper Publishing WeChat |
Useful Links
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Article
Author(s)
Fikile Muriel Mnisi
Full-Text PDF
XML 832 Views
DOI:10.17265/2328-2150/2016.09.002
Affiliation(s)
ABSTRACT
Researchers from all around the world emphasize on the enormous possible
benefits that stem cells may have for the treatment of diseases. However, this
technology is considered morally problematic when the source of the stem cell
is from a human embryo. Nonetheless, there is a consensus that of all the types
of stem cells, hESC (human embryonic stem
cells) are the most promising for particular and important research and
therapies. Yet, there are controversial issues regarding the “killing” of the human embryo
for stem cell derivation. There are two general ethical conditions that should
govern the instrumental use of embryo. One of them, the principle of subsidiarity,
which is defined as “a state we have that
we have to choose the less contentious means of achieving the intended goal”. Based on this
principle, we ought only to use
hESC when there are no other alternatives, which are less morally
controversially. Subsidiarity is based on the assumption that there is
something ethically unsound about the use of hESC. However, this principle only
makes sense if it is based on consistently upheld views of the moral status of
embryo, moreover, the law should also not limit or prohibit hESC research based
on this principle. In this paper, I argue—using the South African law for hESC technology—that criterion for deciding which type of stem cells to use should be
based on their potential and suitability for advancing scientific knowledge and
development of new therapies which will be greatly beneficial in alleviating
human suffering.
KEYWORDS
Principle of subsidiarity, stem cell, human embryo, human embryonic stem cell.
Cite this paper
Mnisi, F. M. 2016. “A Critique on the Application of the Principle of Subsidiarity Concerning Human Embryonic Stem Cell Research in South Africa.” Journal of Pharmacy and Pharmacology 4 (9): 472-485.
References




